ClinicalTrials.gg
CompletedNCT03375632Updated Sep 24, 2018

Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)

A Phase 1 interventional study of FYU-981 in Hyperuricemia With or Without Gout, sponsored by Mochida Pharmaceutical Company, Ltd.. Completed at 1 site in Japan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-09-24.

Sponsored by Mochida Pharmaceutical Company, Ltd. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
20 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing dotinurad in Gout — 4 open to participants now, 4 under way, 1 of them phase 3. dotinurad · Gout.

Enrollment
9th of 10
26 · median 202
Started
2018
with 1 other
Phase 1
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
2 of 10
Mochida Pharmaceutical Company, Ltd.

Among the 10 studies testing dotinurad in Gout, this one is the 9th largest by enrollment, is one of 2 that started in 2018, is the only one in phase 1, and was the 3rd registered.

Gout

347 studies on the registry are indexed under Gout; 49 are open to participants now.

Browse Gout studies →

Open to participants now

4 of the 10 studies testing dotinurad in Gout are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About dotinurad

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 30 Gout studies recruiting now, 14 (47%) set no upper age limit and 10 (33%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 20 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing dotinurad in Gout, or all of them as a file.
02

Study summary

To investigate the pharmacodynamics and safety of FYU-981 administered orally once a day for 14 weeks, to uric acid-overproduction type or uric acid-underexcretion type of male hyperuricemic outpatients with or without gout.

03

Conditions studied

  • Hyperuricemia With or Without Gout

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Serum urate level:

    • >= 7.0mg/dL in patients with gouty nodule or with history of gout, or >=8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
  • Disease type in the classification of hyperuricemia: Uric acid-overproduction type or Uric acid-underexcretion type
  • Outpatients

Exclusion criteria

Exclusion Criteria:

  • Gouty arthritis within 14 days before randomized allocation
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Uric acid-overproduction Type

    Drug: FYU-981

  • Experimental
    Uric acid-underexcretion Type

    Drug: FYU-981

Interventions

  • Oral daily dosing for 14 weeks

06

What researchers measure

Primary outcomes

  1. Pharmacodynamics (Amount of uric acid excreted in urine)

    Time frame: 2-week

  2. Pharmacodynamics (Amount of uric acid excreted in urine)

    Time frame: 6-week

  3. Pharmacodynamics (Amount of uric acid excreted in urine)

    Time frame: 10-week

  4. Pharmacodynamics (Amount of uric acid excreted in urine)

    Time frame: 14-week

07

Study locations

1 site
  • Mochida Investigational sites
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in May 2018, 4 months.

Of 37 industry-sponsored phase 1 interventional studies under Gout, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 40 studies reached it within 6 months; a quarter within 1 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2017
First posted
Dec 18, 2017
StartActual
Jan 4, 2018
Primary completionActual
May 29, 2018
CompletionActual
Jun 5, 2018
Last update
Sep 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03375632
Lead sponsor
Mochida Pharmaceutical Company, Ltd.
Collaborators
Fuji Yakuhin Co., Ltd.
Responsible party
Sponsor
First posted
Dec 18, 2017
Start date
Jan 4, 2018
Primary completion
May 29, 2018
Completion
Jun 5, 2018
Last update
Sep 24, 2018

Study contacts

Kazuki Furuno
study director · Clinical Research Department

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dotinurad

Start the discussion